Cornelius Marvin Geissen, DO | |
555 Glasgow St, Stowe, PA 19464-6557 | |
(484) 945-0770 | |
(484) 945-0648 |
Full Name | Cornelius Marvin Geissen |
---|---|
Gender | Male |
Speciality | Family Medicine |
Location | 555 Glasgow St, Stowe, Pennsylvania |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1518938646 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | OS004823L (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Cornelius Marvin Geissen, DO 1610 Medical Dr, Suite 310, Pottstown, PA 19464-3292 Ph: (484) 945-0405 | Cornelius Marvin Geissen, DO 555 Glasgow St, Stowe, PA 19464-6557 Ph: (484) 945-0770 |
News Archive
According to consumer group CHOICE the available vitamin-enhanced water products, produced by such companies as Nutrient Water, Smart Water and Vitamin Water, often contain high levels of sugar and in some cases were branded in a way that suggested they contained ingredients that were non-existent.
As the second anniversary of Hurricane Katrina's landfall approaches, new analysis by the Kaiser Family Foundation of its household survey of people in the New Orleans area shows that more than four in 10 (43 percent) adults reported at least one health care access problem in the aftermath of Hurricane Katrina.
Recent advances in cancer therapeutics have led to the discovery of biomarkers that can predict patient response to certain drugs. Screening for mutations in the epidermal growth factor receptor (EGRF) prior to non-small cell lung cancer treatment, for example, has been shown to indentify patients who are likely to respond to treatment with erlontinib. This maximizes the drug's impact, and spares patients who are not likely to benefit from being subjected to potentially debilitating side effects.
A new study, which was conducted by Vishala Mishra and Joseph P. Dexter at Madras Medical College, Chennai, India, suggests that the infamous pause in the administration of the Johnson & Johnson (J&J)/Janssen COVID-19 vaccine, advised by the FDA, has left doubt about the veracity of vaccine safety claims. This is a development that may have engendered vaccine hesitancy in a segment of the population.
› Verified 5 days ago